About this trial
The purpose of this study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by relapse free survival (RFS).
Patient Profile
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St Vincents University Hospital, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | R3767-ONC-2055 |
|---|---|
| Number: | 22-25 |
| Full Title: | A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma |
| Principal Investigator: | Prof Derek Power |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Regeneron |
| Recruitment Started: |
Global: 16-Jan-2023 Ireland: Q4 2023 |
| Global Recruitment Target: | 1530 |
|---|---|
| Ireland Recruitment Target: | 27 |